Triacylglycerol turnover in the failing heart

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1861, Issue 10, 2016, Pages 1492-1499

  Carley, Andrew N ^a   Lewandowski, E Douglas ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

Diabetes; Fatty acids; Heart failure; Hypertrophy; Metabolism; Triglyceride

Indexed keywords

ACYL COENZYME A; TRIACYLGLYCEROL; FATTY ACID;

BIOSYNTHESIS; CATABOLISM; CELL FUNCTION; DIABETES MELLITUS; ENERGY METABOLISM; ENZYME ACTIVATION; FATTY ACID OXIDATION; GENE EXPRESSION REGULATION; HEART FAILURE; HEART MUSCLE METABOLISM; HUMAN; LIPID STORAGE; LIPOLYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TURNOVER TIME; ANIMAL; METABOLISM; MITOCHONDRION; OXIDATION REDUCTION REACTION;

ANIMALS; FATTY ACIDS; HEART FAILURE; HUMANS; MITOCHONDRIA; OXIDATION-REDUCTION; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

EID: 84962159707     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2016.03.012     Document Type: Review

References (81)

1. [1] Braunwald, E., Heart failure. JACC Heart Fail. 1 (2013), 1–20.
2. [2] Ingwall, J.S., Weiss, R.G., Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ. Res. 95 (2004), 135–145.
3. [3] Ingwall, J.S., Energy metabolism in heart failure and remodelling. Cardiovasc. Res. 81 (2009), 412–419.
4. [4] Sorokina, N., O'Donnell, J.M., McKinney, R.D., Pound, K.M., Woldegiorgis, G., LaNoue, K.F., Ballal, K., Taegtmeyer, H., Buttrick, P.M., Lewandowski, E.D., Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts. Circulation 115 (2007), 2033–2041.
5. [5] Pound, K.M., Sorokina, N., Ballal, K., Berkich, D.A., Fasano, M., Lanoue, K.F., Taegtmeyer, H., O'Donnell, J.M., Lewandowski, E.D., Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy. Circ. Res. 104 (2009), 805–812.
6. [6] How, O.J., Aasum, E., Severson, D.L., Chan, W.Y., Essop, M.F., Larsen, T.S., Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 55 (2006), 466–473.
7. [7] Buchanan, J., Mazumder, P.K., Hu, P., Chakrabarti, G., Roberts, M.W., Yun, U.J., Cooksey, R.C., Litwin, S.E., Abel, E.D., Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 146 (2005), 5341–5349.
8. [8] Lehman, J.J., Kelly, D.P., Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail. Rev. 7 (2002), 175–185.
9. [9] O'Donnell, J.M., Fields, A.D., Sorokina, N., Lewandowski, E.D., The absence of endogenous lipid oxidation in early stage heart failure exposes limits in lipid storage and turnover. J. Mol. Cell. Cardiol. 44 (2008), 315–322.
10. [10] Lahey, R., Wang, X., Carley, A.N., Lewandowski, E.D., Dietary fat supply to failing hearts determines dynamic lipid signaling for nuclear receptor activation and oxidation of stored triglyceride. Circulation 130 (2014), 1790–1799.
11. [11] Chokshi, A., Drosatos, K., Cheema, F.H., Ji, R., Khawaja, T., Yu, S., Kato, T., Khan, R., Takayama, H., Knöll, R., Milting, H., Chung, C.S., Jorde, U., Naka, Y., Mancini, D.M., Goldberg, I.J., Schulze, P.C., Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation 125 (2012), 2844–2853.
12. [12] Kolwicz, S.C., Olson, D.P., Marney, L.C., Garcia-Menendez, L., Synovec, R.E., Tian, R., Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circ. Res. 111 (2012), 728–738.
13. [13] Lewandowski, E.D., Fischer, S.K., Fasano, M., Banke, N.H., Walker, L.A., Huqi, A., Wang, X., Lopaschuk, G.D., O'Donnell, J.M., Acute liver carnitine palmitoyltransferase I overexpression recapitulates reduced palmitate oxidation of cardiac hypertrophy. Circ. Res. 112 (2013), 57–65.
14. [14] Carley, A.N., Taegtmeyer, H., Lewandowski, E.D., Matrix revisited: mechanisms linking energy substrate metabolism to the function of the heart. Circ. Res. 114 (2014), 717–729.
15. [15] Lewandowski, E.D., O'donnell, J.M., Scholz, T.D., Sorokina, N., Buttrick, P.M., Recruitment of NADH shuttling in pressure-overloaded and hypertrophic rat hearts. Am. J. Physiol. Cell Physiol. 292 (2007), C1880–C1886.
16. [16] Abel, E.D., Doenst, T., Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy. Cardiovasc. Res. 90 (2011), 234–242.
17. [17] Doenst, T., Nguyen, T.D., Abel, E.D., Cardiac metabolism in heart failure: implications beyond ATP production. Circ. Res. 113 (2013), 709–724.
18. [18] Kolwicz, S.C., Purohit, S., Tian, R., Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ. Res. 113 (2013), 603–616.
19. [19] Zhabyeyev, P., Gandhi, M., Mori, J., Basu, R., Kassiri, Z., Clanachan, A., Lopaschuk, G.D., Oudit, G.Y., Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload. Cardiovasc. Res. 97 (2013), 676–685.
20. [20] Leong, H.S., Brownsey, R.W., Kulpa, J.E., Allard, M.F., Glycolysis and pyruvate oxidation in cardiac hypertrophy—why so unbalanced?. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 135 (2003), 499–513.
21. [21] Masoud, W.G., Ussher, J.R., Wang, W., Jaswal, J.S., Wagg, C.S., Dyck, J.R., Lygate, C.A., Neubauer, S., Clanachan, A.S., Lopaschuk, G.D., Failing mouse hearts utilize energy inefficiently and benefit from improved coupling of glycolysis and glucose oxidation. Cardiovasc. Res. 101 (2014), 30–38.
22. [22] Fillmore, N., Mori, J., Lopaschuk, G.D., Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br. J. Pharmacol. 171 (2014), 2080–2090.
23. [23] Haemmerle, G., Moustafa, T., Woelkart, G., Buttner, S., Schmidt, A., van de Weijer, T., Hesselink, M., Jaeger, D., Kienesberger, P.C., Zierler, K., Schreiber, R., Eichmann, T., Kolb, D., Kotzbeck, P., Schweiger, M., Kumari, M., Eder, S., Schoiswohl, G., Wongsiriroj, N., Pollak, N.M., Radner, F.P., Preiss-Landl, K., Kolbe, T., Rulicke, T., Pieske, B., Trauner, M., Lass, A., Zimmermann, R., Hoefler, G., Cinti, S., Kershaw, E.E., Schrauwen, P., Madeo, F., Mayer, B., Zechner, R., ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1. Nat. Med. 17 (2011), 1076–1085.
24. [24] Banke, N.H., Wende, A.R., Leone, T.C., O'Donnell, J.M., Abel, E.D., Kelly, D.P., Lewandowski, E.D., Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor PPARalpha. Circ. Res. 107 (2010), 233–241.
25. [25] Khan, S.A., Sathyanarayan, A., Mashek, M.T., Ong, K.T., Wollaston-Hayden, E.E., Mashek, D.G., ATGL-catalyzed lipolysis regulates SIRT1 to control PGC-1α/PPAR-α signaling. Diabetes 64 (2015), 418–426.
26. [26] Liu, L., Shi, X., Bharadwaj, K.G., Ikeda, S., Yamashita, H., Yagyu, H., Schaffer, J.E., Yu, Y.H., Goldberg, I.J., DGAT1 expression increases heart triglyceride content but ameliorates lipotoxicity. J. Biol. Chem. 284 (2009), 36312–36323.
27. [27] Liu, L., Yu, S., Khan, R.S., Homma, S., Schulze, P.C., Blaner, W.S., Yin, Y., Goldberg, I.J., Diacylglycerol acyl transferase 1 overexpression detoxifies cardiac lipids in PPARγ transgenic mice. J. Lipid Res. 53 (2012), 1482–1492.
28. [28] Aubert, G., Vega, R.B., Kelly, D.P., Perturbations in the gene regulatory pathways controlling mitochondrial energy production in the failing heart. Biochim. Biophys. Acta 1833 (2013), 840–847.
29. [29] Kassiotis, C., Rajabi, M., Taegtmeyer, H., Metabolic reserve of the heart: the forgotten link between contraction and coronary flow. Prog. Cardiovasc. Dis. 51 (2008), 74–88.
30. [30] Sharma, S., Adrogue, J.V., Golfman, L., Uray, I., Lemm, J., Youker, K., Noon, G.P., Frazier, O.H., Taegtmeyer, H., Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 18 (2004), 1692–1700.
31. [31] McGavock, J.M., Lingvay, I., Zib, I., Tillery, T., Salas, N., Unger, R., Levine, B.D., Raskin, P., Victor, R.G., Szczepaniak, L.S., Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 116 (2007), 1170–1175.
32. [32] Harmancey, R., Taegtmeyer, H., The complexities of diabetic cardiomyopathy: lessons from patients and animal models. Curr. Diab. Rep. 8 (2008), 243–248.
33. [33] Lydell, C.P., Chan, A., Wambolt, R.B., Sambandam, N., Parsons, H., Bondy, G.P., Rodrigues, B., Popov, K.M., Harris, R.A., Brownsey, R.W., Allard, M.F., Pyruvate dehydrogenase and the regulation of glucose oxidation in hypertrophied rat hearts. Cardiovasc. Res. 53 (2002), 841–851.
34. [34] Sambandam, N., Lopaschuk, G.D., Brownsey, R.W., Allard, M.F., Energy metabolism in the hypertrophied heart. Heart Fail. Rev. 7 (2002), 161–173.
35. [35] Stanley, W.C., Recchia, F.A., Lopaschuk, G.D., Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85 (2005), 1093–1129.
36. [36] Carley, A.N., Taglieri, D.M., Bi, J., Solaro, R.J., Lewandowski, E.D., Metabolic efficiency promotes protection from pressure overload in hearts expressing slow skeletal troponin I. Circ. Heart Fail. 8 (2015), 119–127.
37. [37] Liu, L., Yu, S., Khan, R.S., Ables, G.P., Bharadwaj, K.G., Hu, Y., Huggins, L.A., Eriksson, J.W., Buckett, L.K., Turnbull, A.V., Ginsberg, H.N., Blaner, W.S., Huang, L.S., Goldberg, I.J., DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle. J. Lipid Res. 52 (2011), 732–744.
38. [38] Chakravarthy, M.V., Lodhi, I.J., Yin, L., Malapaka, R.R., Xu, H.E., Turk, J., Semenkovich, C.F., Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell 138 (2009), 476–488.
39. [39] Kienesberger, P.C., Pulinilkunnil, T., Nagendran, J., Young, M.E., Bogner-Strauss, J.G., Hackl, H., Khadour, R., Heydari, E., Haemmerle, G., Zechner, R., Kershaw, E.E., Dyck, J.R., Early structural and metabolic cardiac remodelling in response to inducible adipose triglyceride lipase ablation. Cardiovasc. Res. 99 (2013), 442–451.
40. [40] Eichmann, T.O., Kumari, M., Haas, J.T., Farese, R.V., Zimmermann, R., Lass, A., Zechner, R., Studies on the substrate and stereo/regioselectivity of adipose triglyceride lipase, hormone-sensitive lipase, and diacylglycerol-O-acyltransferases. J. Biol. Chem. 287 (2012), 41446–41457.
41. [41] Zierler, K.A., Jaeger, D., Pollak, N.M., Eder, S., Rechberger, G.N., Radner, F.P., Woelkart, G., Kolb, D., Schmidt, A., Kumari, M., Preiss-Landl, K., Pieske, B., Mayer, B., Zimmermann, R., Lass, A., Zechner, R., Haemmerle, G., Functional cardiac lipolysis in mice critically depends on comparative gene identification-58. J. Biol. Chem. 288 (2013), 9892–9904.
42. [42] Wang, H., Sreenivasan, U., Sreenevasan, U., Hu, H., Saladino, A., Polster, B.M., Lund, L.M., Gong, D.W., Stanley, W.C., Sztalryd, C., Perilipin 5, a lipid droplet-associated protein, provides physical and metabolic linkage to mitochondria. J. Lipid Res. 52 (2011), 2159–2168.
43. [43] Kuramoto, K., Okamura, T., Yamaguchi, T., Nakamura, T.Y., Wakabayashi, S., Morinaga, H., Nomura, M., Yanase, T., Otsu, K., Usuda, N., Matsumura, S., Inoue, K., Fushiki, T., Kojima, Y., Hashimoto, T., Sakai, F., Hirose, F., Osumi, T., Perilipin 5, a lipid droplet-binding protein, protects heart from oxidative burden by sequestering fatty acid from excessive oxidation. J. Biol. Chem. 287 (2012), 23852–23863.
44. [44] Park, T.S., Goldberg, I.J., Sphingolipids, lipotoxic cardiomyopathy, and cardiac failure. Heart Fail. Clin. 8 (2012), 633–641.
45. [45] Geraldes, P., King, G.L., Activation of protein kinase C isoforms and its impact on diabetic complications. Circ. Res. 106 (2010), 1319–1331.
46. [46] Szendroedi, J., Yoshimura, T., Phielix, E., Koliaki, C., Marcucci, M., Zhang, D., Jelenik, T., Müller, J., Herder, C., Nowotny, P., Shulman, G.I., Roden, M., Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 9597–9602.
47. [47] Finck, B.N., Lehman, J.J., Leone, T.C., Welch, M.J., Bennett, M.J., Kovacs, A., Han, X., Gross, R.W., Kozak, R., Lopaschuk, G.D., Kelly, D.P., The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109 (2002), 121–130.
48. [48] Finck, B.N., Han, X., Courtois, M., Aimond, F., Nerbonne, J.M., Kovacs, A., Gross, R.W., Kelly, D.P., A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 1226–1231.
49. [49] Burkart, E.M., Sambandam, N., Han, X., Gross, R.W., Courtois, M., Gierasch, C.M., Shoghi, K., Welch, M.J., Kelly, D.P., Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J. Clin. Invest. 117 (2007), 3930–3939.
50. [50] Baranowski, M., Błachnio, A., Zabielski, P., Górski, J., PPARalpha agonist induces the accumulation of ceramide in the heart of rats fed high-fat diet. J. Physiol. Pharmacol. 58 (2007), 57–72.
51. [51] Osumi, T., Kuramoto, K., Heart lipid droplets and lipid droplet-binding proteins: biochemistry, physiology, and pathology. Exp. Cell Res., 2015.
52. [52] Li, L., Zhang, H., Wang, W., Hong, Y., Wang, J., Zhang, S., Xu, S., Shu, Q., Li, J., Yang, F., Zheng, M., Qian, Z., Liu, P., Comparative proteomics reveals abnormal binding of ATGL and dysferlin on lipid droplets from pressure overload-induced dysfunctional rat hearts. Sci. Rep., 6, 2016, 19782.
53. [53] Kimmel, A.R., Sztalryd, C., Perilipin 5, a lipid droplet protein adapted to mitochondrial energy utilization. Curr. Opin. Lipidol. 25 (2014), 110–117.
54. [54] Wang, H., Lei, M., Hsia, R.C., Sztalryd, C., Analysis of lipid droplets in cardiac muscle. Methods Cell Biol. 116 (2013), 129–149.
55. [55] Herms, A., Bosch, M., Reddy, B.J., Schieber, N.L., Fajardo, A., Rupérez, C., Fernández-Vidal, A., Ferguson, C., Rentero, C., Tebar, F., Enrich, C., Parton, R.G., Gross, S.P., Pol, A., AMPK activation promotes lipid droplet dispersion on detyrosinated microtubules to increase mitochondrial fatty acid oxidation. Nat. Commun., 6, 2015, 7176.
56. [56] Saddik, M., Lopaschuk, G.D., Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J. Biol. Chem. 266 (1991), 8162–8170.
57. [57] Goodwin, G.W., Taylor, C.S., Taegtmeyer, H., Regulation of energy metabolism of the heart during acute increase in heart work. J. Biol. Chem. 273 (1998), 29530–29539.
58. [58] Saddik, M., Lopaschuk, G.D., Triacylglycerol turnover in isolated working hearts of acutely diabetic rats. Can. J. Physiol. Pharmacol. 72 (1994), 1110–1119.
59. [59] Soma, M.R., Mims, M.P., Chari, M.V., Rees, D., Morrisett, J.D., Triglyceride metabolism in 3T3-L1 cells. An in vivo 13C NMR study. J. Biol. Chem. 267 (1992), 11168–11175.
60. [60] Guo, W., Choi, J.K., Kirkland, J.L., Corkey, B.E., Hamilton, J.A., Incorporation of [1-13C]oleate into cellular triglycerides in differentiating 3T3L1 cells. Lipids 34 (1999), 825–831.
61. [61] O'Donnell, J.M., Zampino, M., Alpert, N.M., Fasano, M.J., Geenen, D.L., Lewandowski, E.D., Accelerated triacylglycerol turnover kinetics in hearts of diabetic rats include evidence for compartmented lipid storage. Am. J. Physiol. Endocrinol. Metab. 290 (2006), E448–E455.
62. [62] Kolwicz, S.C., Liu, L., Goldberg, I.J., Tian, R., Enhancing cardiac triacylglycerol metabolism improves recovery from ischemic stress. Diabetes 64 (2015), 2817–2827.
63. [63] Banke, N.H., Lewandowski, E.D., Impaired cytosolic NADH shuttling and elevated UCP3 contribute to inefficient citric acid cycle flux support of postischemic cardiac work in diabetic hearts. J. Mol. Cell. Cardiol. 79 (2015), 13–20.
64. [64] Kienesberger, P.C., Pulinilkunnil, T., Sung, M.M., Nagendran, J., Haemmerle, G., Kershaw, E.E., Young, M.E., Light, P.E., Oudit, G.Y., Zechner, R., Dyck, J.R., Myocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunction. Mol. Cell. Biol. 32 (2012), 740–750.
65. [65] Listenberger, L.L., Han, X., Lewis, S.E., Cases, S., Farese, R.V. Jr., Ory, D.S., Schaffer, J.E., Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 3077–3082.
66. [66] Russo, S.B., Ross, J.S., Cowart, L.A., Sphingolipids in obesity, type 2 diabetes, and metabolic disease. Handb. Exp. Pharmacol., 2013, 373–401.
67. [67] Hu, W., Ross, J., Geng, T., Brice, S.E., Cowart, L.A., Differential regulation of dihydroceramide desaturase by palmitate versus monounsaturated fatty acids: implications for insulin resistance. J. Biol. Chem. 286 (2011), 16596–16605.
68. [68] Guo, W., Kirkland, J.L., Corkey, B., Hamilton, J.A., A 13C nuclear magnetic resonance study of free fatty acid incorporation in acylated lipids in differentiating preadipocytes. Lipids 33 (1998), 449–454.
69. [69] Aasum, E., Belke, D.D., Severson, D.L., Riemersma, R.A., Cooper, M., Andreassen, M., Larsen, T.S., Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am. J. Physiol. Heart Circ. Physiol. 283 (2002), H949–H957.
70. [70] Murphy, E.J., Barcelo-Coblijn, G., Binas, B., Glatz, J.F., Heart fatty acid uptake is decreased in heart fatty acid-binding protein gene-ablated mice. J. Biol. Chem. 279 (2004), 34481–34488.
71. [71] Watt, M.J., Hoy, A.J., Muoio, D.M., Coleman, R.A., Distinct roles of specific fatty acids in cellular processes: implications for interpreting and reporting experiments. Am. J. Physiol. Endocrinol. Metab. 302 (2012), E1–E3.
72. [72] Carley, A.N., Bi, J., Wang, X., Banke, N.H., Dyck, J.R., O'Donnell, J.M., Lewandowski, E.D., Multiphasic triacylglycerol dynamics in the intact heart during acute in vivo overexpression of CD36. J. Lipid Res. 54 (2013), 97–106.
73. [73] Carley, A.N., Kleinfeld, A.M., Fatty acid (FFA) transport in cardiomyocytes revealed by imaging unbound FFA is mediated by an FFA pump modulated by the CD36 protein. J. Biol. Chem. 286 (2011), 4589–4597.
74. [74] Zhou, L., Huang, H., Yuan, C.L., Keung, W., Lopaschuk, G.D., Stanley, W.C., Metabolic response to an acute jump in cardiac workload: effects on malonyl-CoA, mechanical efficiency, and fatty acid oxidation. Am. J. Physiol. Heart Circ. Physiol. 294 (2008), H954–H960.
75. [75] Pulinilkunnil, T., Kienesberger, P.C., Nagendran, J., Sharma, N., Young, M.E., Dyck, J.R., Cardiac-specific adipose triglyceride lipase overexpression protects from cardiac steatosis and dilated cardiomyopathy following diet-induced obesity. Int. J. Obes. 38 (2014), 205–215.
76. [76] Pulinilkunnil, T., Kienesberger, P.C., Nagendran, J., Waller, T.J., Young, M.E., Kershaw, E.E., Korbutt, G., Haemmerle, G., Zechner, R., Dyck, J.R., Myocardial adipose triglyceride lipase overexpression protects diabetic mice from the development of lipotoxic cardiomyopathy. Diabetes 62 (2013), 1464–1477.
77. [77] Sack, M.N., Rader, T.A., Park, S., Bastin, J., McCune, S.A., Kelly, D.P., Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94 (1996), 2837–2842.
78. [78] Barger, P.M., Brandt, J.M., Leone, T.C., Weinheimer, C.J., Kelly, D.P., Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J. Clin. Invest. 105 (2000), 1723–1730.
79. [79] Park, T.S., Hu, Y., Noh, H.L., Drosatos, K., Okajima, K., Buchanan, J., Tuinei, J., Homma, S., Jiang, X.C., Abel, E.D., Goldberg, I.J., Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J. Lipid Res. 49 (2008), 2101–2112.
80. [80] Nagendran, J., Kienesberger, P.C., Pulinilkunnil, T., Zordoky, B.N., Sung, M.M., Kim, T., Young, M.E., Dyck, J.R., Cardiomyocyte specific adipose triglyceride lipase overexpression prevents doxorubicin induced cardiac dysfunction in female mice. Heart 99 (2013), 1041–1047.
81. [81] Madrazo, J.A., Kelly, D.P., The PPAR trio: regulators of myocardial energy metabolism in health and disease. J. Mol. Cell. Cardiol. 44 (2008), 968–975.